The latter is quite important concerning EGFR mutant NSCLC treatment with ICIs because assessing the expression of PD-L1 molecules on tumor cells may help personalize immunotherapy and improve its outcomes. This evidence concerns the gene EGFR and non-small cell lung carcinoma.